Naftin

Manufacturer
Sebela Pharmaceuticals Inc. | DPT Laboratories, Ltd.
Effective date
2024-11-11
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
5
Source
legacy-cache
Hydrated at
2026-08-01 20:49:36

Label at a glance#

ProductNaftin
Active ingredientNAFTIFINE HYDROCHLORIDE
Label structure14 sections

Indications and uses

Naftin ® Gel, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans * Efficacy for this organism in this organ system was studied in fewer than 10 infections. , Epidermophyton floccosum * .

Dosage and administration

A sufficient quantity of Naftin ® Gel, 1% should be gently massaged into the affected and surrounding skin areas twice a day, in the morning and evening. The hands should be washed after application. If no clinical improvement is seen after four weeks of treatment with Naftin ® Gel, 1%, the patient should be re-evaluated.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx ONLY

DESCRIPTION

DESCRIPTION SECTION

Naftin ® Gel, 1% contains the synthetic, broad-spectrum, antifungal agent naftifine hydrochloride. Naftin ® Gel, 1% is for topical use only.

CHEMICAL NAME

SPL UNCLASSIFIED SECTION

(E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride. Naftifine hydrochloride has an empirical formula of C 21H 21N•HCl and a molecular weight of 323.86.

Chemical StructureChemical Structure

Contains

SPL UNCLASSIFIED SECTION

Active Ingredient

SPL UNCLASSIFIED SECTION

Naftifine hydrochloride1%.
Inactive Ingredients

SPL UNCLASSIFIED SECTION

Naftin ® Gel, 1% contains polysorbate 80, carbomer 934P, diisopropanolamine, edetate disodium, alcohol (52%v/v), and purified water.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Naftifine Hydrochloride is a synthetic allylamine derivative. The following in vitro data are available but their clinical significance is unknown. Naftifine hydrochloride has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms, including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum, Microsporum canis, Microsporum audouini, and Microsporum gypseum, and fungistatic activity against Candida species, including Candida albicans. Naftin ® Gel, 1% has only been shown to be clinically effective against the disease entities listed in the INDICATIONS AND USAGE section.

Although the exact mechanism of action against fungi is not known, naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells.

Pharmacokinetics

PHARMACOKINETICS SECTION

In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes.

Following single topical applications of 3H- labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed. Naftifine and/or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Naftin ® Gel, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans * 1 , Epidermophyton floccosum * 1 .

1 Efficacy for this organism in this organ system was studied in fewer than 10 infections.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Naftin ® Gel, 1% is contraindicated in individuals who have shown hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

Naftin ® Gel, 1% is for topical use only and not for ophthalmic use.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Naftin ® Gel, 1%, is for external use only. If irritation or sensitivity develops with the use of Naftin ® Gel, 1%, treatment should be discontinued and appropriate therapy instituted. Diagnosis of the disease should be confirmed either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium.

Information for patients

INFORMATION FOR PATIENTS SECTION

The patient should be told to:

  1. Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician.
  2. Keep Naftin ® Gel, 1% away from the eyes, nose, mouth and other mucous membranes.

Carcinogenesis, mutagenesis, impairment of fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

In a 2-year dermal carcinogenicity study, naftifine hydrochloride cream was administered to Sprague-Dawley rats at topical doses of 1%, 2% and 3% (10, 20, and 30 mg/kg/day naftifine hydrochloride). No drug-related tumors were noted in this study up to the highest dose evaluated in this study of 30 mg/kg/day [3.6 times the maximum recommended human dose (MRHD) based on mg/m2 comparison].

Naftifine hydrochloride revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames assay and Chinese hamster ovary cell chromosome aberration assay) and one in vivo genotoxicity test (mouse bone marrow micronucleus assay).

Oral administration of naftifine hydrochloride to rats, throughout mating, gestation, parturition and lactation, demonstrated no effects on growth, fertility or reproduction, at doses up to 100 mg/kg/day (12 times MRHD based on mg/m 2 comparison).

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Naftin ® Gel,1 % is administered to a nursing woman.

Pediatric use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

During clinical trials with Naftin ® Gel, 1%. the incidence of adverse reactions was as follows: burning/stinging (5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), skin tenderness (0.5%).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

A sufficient quantity of Naftin ® Gel, 1% should be gently massaged into the affected and surrounding skin areas twice a day, in the morning and evening. The hands should be washed after application. If no clinical improvement is seen after four weeks of treatment with Naftin ® Gel, 1%, the patient should be re-evaluated.

HOW SUPPLIED

HOW SUPPLIED SECTION

Naftin ® (naftifine hydrochloride) Gel, 1% is supplied in collapsible tubes in the following sizes

  • 40g – NDC 54766-770-40
  • 60g – NDC 54766-770-60
  • 90g – NDC 54766-770-90

STORAGE AND HANDLING SECTION

Note: Store Naftin ® Gel, 1% at room temperature.

SPL UNCLASSIFIED SECTION

Distributed by Sebela Pharmaceuticals Inc.

645 Hembree Parkway, Suite I

Roswell, Georgia 30076

www.sebelapharma.com

Toll Free 1-844-732-3521


© 2018 Sebela Pharmaceuticals Inc. All rights reserved.

Naftin is a registered trademark of Sebela International Limited.

Rev. May 2018

PI 77040001

PRINCIPAL DISPLAY PANEL - 40g Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

40g Carton40g Carton

NDC 54766-770-40

NAFTIN ®

40g gel

NAFTIFINE HCl 1% GEL

Rx Only

PRINCIPAL DISPLAY PANEL - 60g Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

60g Carton60g Carton

NDC 54766-770-60

NAFTIN ®

60g gel

NAFTIFINE HCl 1% GEL

Rx Only

PRINCIPAL DISPLAY PANEL - 90g Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

90g Carton90g Carton

NDC 54766-770-90

NAFTIN ®

90g gel

NAFTIFINE HCl 1% GEL

Rx Only

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54766-770-40GM - Gram54766-770320468a3-fab5-4e59-b585-4547269fc4f212018-07-03
54766-770-60GM - Gram54766-770699f2da4-5a27-4fe6-9c26-d88e50e1395212018-07-03
54766-770-90GM - Gram54766-77091762b66-937f-43ca-91aa-f58c3727ab3c12018-03-08

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54766-77054766-770-40, 54766-770-60, 54766-770-90

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML · Source PDF

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N019356-001NAFTINNAFTIFINE HYDROCHLORIDE1%GEL / TOPICALRLD1990-06-18

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N019356-001NAFTIN1%GEL / TOPICALRLD1990-06-1884e616aacf4f…
2026-08-18 06:07:402026-07N019356-001NAFTIN1%GEL / TOPICALRLD1990-06-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-181e350fbaab3a…
2024-05-31 18:47 UTC2024-05N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-188072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-185d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-184b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-1874a2ff9319b5…
2022-03-09 01:35 UTC2022-03N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-1887673890dc5c…
2021-03-12 10:30 UTC2021-03N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-185aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-188869cabd3fbd…
2020-11-12 02:37 UTC2020-11N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18c0c555d07b60…
2019-12-14 00:12 UTC2019-12N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-183f01610625f2…
2019-09-15 20:21 UTC2019-09N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18b00525d2431f…
2019-07-19 19:46 UTC2019-07N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-186a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-181c564ffb4f44…
2023-12-20 04:57 UTC2023-12N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-189b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-183f0d92c62455…
2023-05-13 08:27 UTC2023-05N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18053a50430f4f…
2023-01-26 05:58 UTC2023-01N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-183bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-183a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N019356-001NAFTIN1%GEL / TOPICALABRLD, RS1990-06-18f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-02-19 14:30 UTC2026-02N019356-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019356-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08N019356-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019356-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019356-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019356-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019356-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019356-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019356-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N019356-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N019356-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N019356-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N019356-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N019356-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N019356-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N019356-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N019356-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N019356-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N019356-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N019356-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N019356-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03N019356-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N019356-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N019356-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N019356-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09N019356-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07N019356-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N019356-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N019356-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N019356-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N019356-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N019356-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N019356-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N019356-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05N019356-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01N019356-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N019356-001AB13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N019356-001AB1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09N019356-001AB1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N019356-001AB1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
26a34216-2d85-08aa-e063-6394a90aeab46371fceb-b98e-86a5-e053-2a91aa0a3d9e2024-11-11Warnings, Adverse reactionsExact identifier
spl id: 26a34216-2d85-08aa-e063-6394a90aeab4
spl set id: 6371fceb-b98e-86a5-e053-2a91aa0a3d9e

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.